Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease
Serum FGF21 independently predicts cachexia in CLD and may facilitate earlier identification of at-risk patients, enabling timely intervention to improve clinical outcomes.
Authors
- Naohiro Yasuura (ORCID: https://orcid.org/0000-0001-9453-9469)
- Zijian Yang (ORCID: https://orcid.org/0000-0002-9271-817X)
- GOKI SUDA
- Takako Tanaka (ORCID: https://orcid.org/0000-0003-2998-7200)
- Shunsuke Ohnishi (ORCID: https://orcid.org/0000-0003-1194-4149)
- Tomoka Yoda
- Takashi Kitagataya
- Akimitsu Meno
- Masatsugu Ohara
- Takuya Sho
- Qingjie Fu
- Osamu Maehara
- Takashi Sasaki
- Risako Kohya
- Naoki Kawagishi
- Masato Nakai
- Naoya Sakamoto
Institutions
- Hokkaido University (JP)
Publication Details
- Journal
- Frontiers in Nutrition
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3389/fnut.2026.1730695
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development